Opinion|Videos|August 6, 2024
Current and Emerging Treatment Options for Neurofibromatosis Type 1 Related Plexiform Neurofibroma
Author(s)Kaleb H. Yohay, MD
A healthcare expert examines Mirdametinib as an investigational treatment for NF1-PN, focusing on its potential role in managing the condition in adolescents and adults who have moved beyond pediatric care.
Advertisement
- Mirdametinib is currently being investigated as a treatment option for adolescents and adults who have transitioned out of adolescent care who are living with NF1-PN. Can you comment on the recent phase II data?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Stem Cells of Secondary Progressive Multiple Sclerosis Drive Increased Proinflammatory T-Cell Activity
2
Postmortem Analysis Reveals Distinct Patterns of Aquaporin-4 in Parkinson Disease and Multiple System Atrophy
3
EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular, Stroke-Related Benefits
4
Optimizing Speech and Movement Therapy to Improve Motor and Nonmotor Symptoms of Parkinson Disease: Cynthia Fox, PhD, CCC-SLP
5